With a closely divided House poised to vote today on whether to expand federal funding of human embryonic stem cell research, opponents are offering fence-sitters what they say is an embryo-friendly alternative: a bill that would foster the use of stem cells from umbilical cords discarded after birth.
The U.S. government is dangling a big carrot — and some wheat and corn — to encourage manufacturers to make more products from biobased materials.
How does Genentech do it? The biotech company focuses on science — not marketing, acquisitions, or patents
U.S. prices for brand-name drugs on average rose at 2.5 times the rate of inflation last year, while generic drug prices remained flat, according to a study released on Tuesday by the nation’s largest lobby for the elderly.
There is no difference between meat and milk from cloned livestock and those foods obtained from conventionally bred cattle, according to a study released today.
As part of an agency-wide initiative to speed development of new medical products through the science of pharmacogenomics, the FDA has issued a final guidance regarding pharmacogenomic data submissions.
India’s government proposed on Friday to change the country’s patent laws to make it illegal to copy patented drugs, a practice that has made cheaper medicines available in India and abroad.
There could be as many as 50 new biotechnology medicines approved for commercial use in the coming months, thanks to advances in biotechnology research and development, according to a study released March 7.
For the second week in a row, buyout rumors and merger speculation sent a number of biotech and specialty pharmaceutical shares higher.
Ad executives and drug company officials say changes in advertising strategies are almost a certainty in the wake of the Vioxx and Celebrex news and new studies showing a consumer backlash.